Publications by authors named "Alex J Ambinder"
Article Synopsis
- Acute myeloid leukaemia (AML) is a serious bone marrow cancer that can be difficult to treat, especially in patients with FLT3 mutations who often don't respond well to current therapies like midostaurin combined with intensive chemotherapy (MIC).
- Researchers analyzed samples from 47 patients with FLT3-MP AML using advanced mass spectrometry and machine learning to find better predictive biomarkers for treatment response, leading to the development of a new model called MPhos.
- The MPhos model showed an impressive predictive accuracy in separate validation cohorts, outperforming the existing FLT3-based method, which could significantly improve treatment decision-making in AML patients.
High-dose post-transplantation cyclophosphamide (PTCy) is an effective platform for prevention of severe graft-versus-host disease (GVHD) after allogeneic bone marrow (BM) transplantation with mismatched unrelated donors (mMUDs). Previous studies evaluating PTCy with mMUDs favored BM allografts over peripheral blood stem cell transplantation (PBSCT) due to concerns that PBSCT may be associated with an increased risk of acute and chronic GVHD. In addition, haploidentical PBSCT is associated with high rates of cytokine release syndrome (CRS), which is another concern with mMUD PBSCT.
View Article and Find Full Text PDF